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Increased Mortality Associated
With Low Use of Clopidogrel in Patients
With Heart Failure and Acute Myocardial Infarction
Not Undergoing Percutaneous Coronary Intervention
A Nationwide Study
Lisbeth Bonde, MD,* Rikke Sorensen, MD,* Emil Loldrup Fosbøl, MD,*
Steen Zabell Abildstrøm, MD, PHD,†‡ Peter Riis Hansen, MD, PHD, DMSC,*
Lars Kober, MD, DMSC,§ Tina Ken Schramm, MD,* Ditte-Marie Bretler, MD,* Peter Weeke, MD,*
Jonas Olesen, MB,* Christian Torp-Pedersen, MD, MDSC,* Gunnar Hilmar Gislason, MD, PHD*
Hellerup, Copenhagen, and Glostrup, Denmark
Objectives We studied the association of clopidogrel with mortality in acute myocardial infarction (AMI) patients with heart
failure (HF) not receiving percutaneous coronary intervention (PCI).
Background Use of clopidogrel after AMI is low in patients with HF, despite the fact that clopidogrel is associated with abso-
lute mortality reduction in AMI patients.
Methods All patients hospitalized with first-time AMI (2000 through 2005) and not undergoing PCI within 30 days from dis-
charge were identified in national registers. Patients with HF treated with clopidogrel were matched by propensity
score with patients not treated with clopidogrel. Similarly, 2 groups without HF were identified. Risks of all-cause
death were obtained by the Kaplan-Meier method and Cox regression analyses.
Results We identified 56,944 patients with first-time AMI. In the matched cohort with HF (n  5,050) and a mean
follow-up of 1.50 years (SD  1.2), 709 (28.1%) and 812 (32.2%) deaths occurred in patients receiving and not
receiving clopidogrel treatment, respectively (p  0.002). The corresponding numbers for patients without HF
(n  6,092), with a mean follow-up of 2.05 years (SD  1.3), were 285 (9.4%) and 294 (9.7%), respectively
(p  0.83). Patients with HF receiving clopidogrel demonstrated reduced mortality (hazard ratio: 0.86; 95% con-
fidence interval: 0.78 to 0.95) compared with patients with HF not receiving clopidogrel. No difference was ob-
served among patients without HF (hazard ratio: 0.98; 95% confidence interval: 0.83 to 1.16).
Conclusions Clopidogrel was associated with reduced mortality in patients with HF who do not undergo PCI after their first-
time AMI, whereas this association was not apparent in patients without HF. Further studies of the benefit of
clopidogrel in patients with HF and AMI are warranted. (J Am Coll Cardiol 2010;55:1300–7) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.057p
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veart failure (HF) complicating acute myocardial infarction
AMI) is associated with a poor prognosis (1,2). Current
uropean and American guidelines recommend dual anti-
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ccepted November 2, 2009.latelet treatment with aspirin and clopidogrel in all patients
ith AMI in the absence of an increased risk of bleeding
3–5). Three major randomized controlled studies have
rovided important knowledge regarding the benefit of
See page 1308
lopidogrel in patients hospitalized with acute coronary
yndrome. One trial investigated the effect of clopidogrel
ersus aspirin (6), another investigated the effect of clopi-
ogrel versus placebo (7), and another showed an effect of
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March 30, 2010:1300–7 Clopidogrel in HF in Connection With MIlopidogrel versus placebo in addition to aspirin (8). A
avorable effect of clopidogrel with respect to the composite
nd point of death, reinfarction, or stroke was found in all
tudies, and in the latter study, also a decreased risk of
ll-cause mortality was found (7–9). Patients with HF
omprised a modest part of the study population in all 3
tudies, and no subgroup analyses of patients with HF were
erformed. The clinical benefit of clopidogrel in AMI
atients with HF is not clarified, which may cause uncer-
ainty and may lead to differences in clinical practice among
hysicians treating this high-risk patient population. This
otion is supported by studies evaluating the implementation of
on–ST-segment elevation myocardial infarction (NSTEMI)
uidelines, which have demonstrated low initiation rates of
lopidogrel in patients not undergoing percutaneous coro-
ary intervention (PCI) and even lower initiation rates of
lopidogrel in patients with HF (10–13).
Patients with HF have an approximately 3% annual risk
f atherothrombotic events, which may be because of the
ignificantly increased platelet activity (14). Indeed, it has
een demonstrated that the addition of clopidogrel to
spirin in patients with HF significantly inhibits the in-
reased platelet activity (15). Whether clopidogrel provides
dditional survival benefit for AMI patients with concom-
tant HF compared with patients without HF is unknown.
his uncertainty prompted us to conduct a nationwide study
xamining the effect of clopidogrel on mortality in a
opulation of patients with and without HF discharged
fter their first-time AMI and not undergoing PCI.
ethods
n Denmark, all citizens are registered with a personal
umber in the Central Population Register, which enables
inkage of information on each individual across different
egisters. The Danish National Patient Register holds
nformation on all hospitalizations in Denmark since 1978,
nd each hospitalization is registered with 1 primary diag-
osis and, if appropriate, a secondary diagnosis according to
he World Health Organization’s International Classifica-
ion of Diseases. The Danish Register of Medicinal Product
tatistics registers all prescriptions dispensed from Danish
harmacies since 1995. Each prescription is coded accord-
ng to the international classification of pharmaceuticals
Anatomic Therapeutical Chemical [ATC] system) and
ncludes information on dispensing date, strength, formu-
ation, quantity dispensed, and affiliation of the doctor
ssuing the prescription. As part of partial coverage of drug
xpenses by the Danish health care system, pharmacies are
equested to register all dispensed prescriptions, ensuring
omplete registration nationwide (16). In Denmark, all cardio-
ascular pharmaceuticals require a prescription, except for
spirin, which is also dispensed as an over-the-counter drug.
opulation. Patients discharged between January 1, 2000,
nd December 31, 2005, after their first-time hospitaliza-
ion for AMI (World Health Organization’s International mlassification of Diseases-10th
evision, codes I21-I22 as the
rimary or secondary diagnosis)
ere identified using the Danish
ational Patient Register. We
ncluded patients aged 30 years
r more who survived for at least
0 days after discharge. Patients
ith PCI (Danish National
oard of Health classification code
FNG02-05) treated within the
rst 30 days after hospitalization
ere excluded. To ensure a homog-
nous study population, we ex-
luded patients with a history of AMI within a minimum of
2 years before hospitalization. Each patient’s vital status as
f December 31, 2005, was obtained from the Central
opulation Register. Comorbidity was defined according to
he modified Ontario AMI mortality prediction rules by
iagnoses from the index admission and 1 year before admis-
ion (17). The use of glucose-lowering therapy (ATC code
10) was used as a proxy for the diagnosis of pharmacologi-
ally treated diabetes. Patients were categorized as patients
ith HF if they had been discharged with the diagnosis code
f HF (World Health Organization’s International Classifica-
ion of Diseases-10th revision, codes I11.0, I42, I50, J81.9)
ithin 1 year of AMI admission or had claimed prescriptions
or loop diuretics (ATC code cC03C) 90 days before admis-
ion to 90 days after discharge (18,19). Severity of HF was
lassified into 4 groups according to average daily dosage of
oop diuretics during the first 90 days after discharge: group
, 0 to 39 mg; group II, 40 to 80 mg; group III, 81 to 160
g; and group IV, 160 mg (18).
edical treatment. We defined initiation of clopidogrel
ATC code B01AC04) if a prescription was claimed within
0 days after discharge and concomitant pharmacotherapy
beta-blockers, angiotensin-converting enzyme inhibitors,
tatins, glucose-lowering drugs, and vitamin K antagonist)
ithin 90 days after discharge, respectively.
tatistical analyses. For descriptive statistics, continuous
ariables are presented as mean values with SD and categorical
ariables are presented as frequencies (Table 1). Statistical
omparisons were performed using the Student t test for
ontinuous variables and the chi-square test for categorical
ata. Significance level was determined as a 2-tailed p value of
0.05. We found a positive interaction between HF and
lopidogrel in the total population and, therefore, stratified the
opulation into 2 cohorts, with and without HF. All further
nalyses were performed separately in the 2 groups. Logistic
egression models were used in the populations with and
ithout HF to estimate the propensity score for claiming a
rescription within 30 days from discharge, that is, each
atient’s probability of receiving clopidogrel. The models were
onditional on baseline covariates, that is, age, gender, calendar
ear, severity of HF (only for patients with HF), concomitant
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
HR  hazard ratio
AMI  acute myocardial
infarction
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary interventionedical treatment, and comorbidity. To account for potential
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Clopidogrel in HF in Connection With MI March 30, 2010:1300–7onfounding, we performed a match-pair analysis based on the
ropensity score for receiving clopidogrel and the period of
ospitalization (2000 through 2001, 2002 through 2003, and
004 through 2005), that is, 2 patients with the same propen-
ity estimate and period were matched; however, 1 patient had
laimed a prescription of clopidogrel and the other patient had
ot. The cohorts were matched by the greedy match algorithm
20). The hazard ratio (HR) for death from all causes was
stimated by univariate Cox proportional hazards analysis with
ndividual lifetime starting at 30 days from discharge. Survival
stimates on the 2 subgroups of the matched population were
alculated separately for each group using the Kaplan-Meier
ethod and were evaluated with the log-rank test.
All analyses were performed with the Statistical Analyt-
cal System, version 9.1 (SAS Institute, Cary, North Caro-
ina). No ethical approval is required for retrospective
egister studies in Denmark.
esults
tudy population and patient characteristics. We iden-
aseline Characteristics: Patients Admitted From 2000 Through 20cute Myoc dial Infarction Without Percutaneous Coronary IntervTable 1 B seli e Charac ristics: Pa ients Admitted F om 200Acute Myocardial Infarction Without Percutaneous Cor
Heart Failur
Clopidogrel No
Total 31,251 2,659 (17.2) 12
Men 17,956 1,453 (54.6) 6
Age (yrs) 68.4 (12.7) 75.1 (10.1)
Year of admittance to hospital
Year 2000–2001 12,516 136 (5.1) 5
Year 2002–2003 10,772 1,119 (42.1) 4
Year 2004–2005 7,963 1,404 (52.8) 2
Comorbidity
Cerebral vascular disease 2,175 207 (7.8) 1
Diabetes with complications 2,069 302 (11.4) 1
Cardiac dysrhythmias 4,294 453 (17.0) 2
Acute renal failure 408 46 (1.7)
Chronic renal failure 600 90 (3.4)
Malignancy 1,315 109 (4.1)
Shock 403 41 (1.5)
Pulmonary edema 684 97 (3.6)
Severity of HF*
Group I 566 113 (4.2)
Group II 9,818 1,702 (64.0) 8
Group III 3,572 606 (22.8) 2
Group IV 845 142 (5.3)
Concomitant pharmacotherapy
Beta-blockers 22,221 2,025 (76.2) 8
ACE inhibitors 13,441 1,606 (60.4) 6
Statins 15,929 1,689 (63.5) 4
Glucose-lowering drugs† 4,251 558 (21.0) 2
Vitamin K antagonist 2,599 225 (8.5) 1
Loop diuretics 14,821 2,566 (96.5) 12
alues are n (%) and/or mean  SD. *Loop diuretics are used as a proxy for heart failure. Accordi
9 mg; group II, 40 to 80 mg; group III, 81 to 160 mg; group IV,  160 mg). †Glucose-lowering d
ACE  angiotensin converting enzyme; HF  heart failure.ified 56,944 patients discharged after their first AMI grom January 1, 2000, through December 31, 2005. A
otal of 40,902 (71.8%) patients did not undergo PCI and
f these, 31,295 (76.5%) patients survived at least 30 days
fter discharge and were eligible for study inclusion. The
election of patients is shown in Figure 1. Of the 31,251
atients included, 6,112 (19.6%) patients were treated
ith clopidogrel and 15,438 (49.4%) were categorized
ith HF. After matching according to propensity score
or receiving clopidogrel, the HF population included
,525 matched pairs; each pair including one patient
reated with clopidogrel and one treated without. Like-
ise, we identified 3,046 matched pairs without HF.
ecause of emigration, 7 patients were lost to follow-up
n the matched populations and were censored at the time
f disappearance. The mean follow-up in the population
ith HF was 1.50 years (SD  1.2) and 2.05 years
SD  1.3) in the population without HF. The matched
opulation included 91.1% of all patients receiving clo-
idogrel in the unmatched population. The propensity
core analysis had a C-statistics value of 0.77, indicating
ith First-Timen and Surviving the First 30 Daysough 2005 With First-Time
y Intervention and Surviving the First 30 Days
15,438) No Heart Failure (n  15,813)
ogrel p Value Clopidogrel No Clopidogrel p Value
2.8) 3,453 (21.8) 12,360 (78.2)
1.1) 0.001 2,240 (64.9) 7,737 (62.6) 0.014
0.7) 0.001 65.5 (12.8) 66.8 (13.3) 0.001
6.1) 0.001 213 (6.2) 6,270 (50.7) 0.001
3.0) 0.001 1,512 (43.8) 3,920 (31.7) 0.001
0.8) 0.001 1,728 (50.0) 2,170 (17.6) 0.001
.3) 0.34 151 (4.4) 751 (6.1) 0.001
.1) 0.001 132 (3.8) 473 (3.8) 0.99
9.1) 0.01 233 (6.7) 1,163 (9.4) 0.001
.1) 0.25 9 (0.3) 88 (0.7) 0.003
.0) 0.27 21 (0.6) 108 (0.9) 0.13
.3) 0.01 84 (2.4) 445 (3.6) 0.001
.9) 0.21 10 (0.3) 109 (0.9) 0.001
.1) 0.29 11 (0.3) 53 (0.4) 0.37
.5) 0.08
3.5) 0.63
3.4) 0.64
.5) 0.74
3.9) 0.001 2,941 (85.2) 9,094 (73.6) 0.001
1.3) 0.001 1,367 (39.6) 3,906 (31.6) 0.001
6.8) 0.001 2,915 (84.4) 6,616 (53.5) 0.001
7.8) 0.001 339 (9.8) 1,078 (8.7) 0.046
2.1) 0.001 123 (3.6) 711 (5.8) 0.001
5.9) 0.15 0 (0.0) 0 (0.0)
erage daily dosage of loop diuretic (furosemide) in the first 90 days after discharge (group I, 0 to
ed as a proxy of diabetes.05 WentioThr
onar
e (n 
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March 30, 2010:1300–7 Clopidogrel in HF in Connection With MIIn the unmatched population, patients with HF were less
ikely to receive clopidogrel compared with patients without
F. The 2 subgroups were unbalanced in selected variables,
or example, year of hospital admittance and concomitant
harmacotherapy. There was an increase in the initiation
ate of clopidogrel during the study period from 1.1% to
7.6% in patients with HF and from 1.7% to 21.7% in
atients without HF, respectively (Table 1). Baseline char-
cteristics of the two matched populations are shown in
able 2.
ll-cause mortality. We found interaction between clopi-
ogrel and HF on the effect of clopidogrel on mortality
HR: 1.17; 95% confidence interval [CI]: 1.00 to 1.33; p 
.048) in the unmatched population. In the matched pop-
lation and among patients with HF, a total of 812 (32.2%)
ied while not being treated with clopidogrel compared
ith 709 (28.1%) deaths in the group receiving clopidogrel
p  0.002). In patients without HF, 294 (9.7%) died
ithout clopidogrel treatment and 285 (9.4%) died in the
roup that received clopidogrel (p  0.83) (Fig. 2). Results
f the Cox proportional hazards analysis for death are
llustrated in Figure 3. We found a decreased risk of death
ssociated with clopidogrel in the HF cohort (HR: 0.86;
5% CI: 0.78 to 0.95; p  0.002). The effect of clopidogrel
as not significant in the cohort without HF (HR: 0.98;
5% CI: 0.83 to 1.16; p  0.83).
dditional analyses. We performed Cox proportional
Figure 1 Population Selection Process
Identification of 4 propensity score-matched cohorts: 2 cohorts with heart failure (
nary intervention; / clopidogrel  patients treated with or without clopidogrel;
PCI.azards analysis for death in the unmatched population Adjusting for all baseline variables. In the group with HF, we
ound a decreased risk of death associated with clopidogrel
n HF patients (HR; 0.88; 95% CI: 0.81 to 0.96; p 0.004)
ompared with no use of clopidogrel. Clopidogrel use in the
roup without HF showed no level of significance (HR:
.96; 95% CI: 0.84 to 1.09; p  0.50). In the matched
opulation, we divided patients with HF into 2 subgroups,
ne group including patients identified by the discharge
iagnosis codes of HF and another with patients identified
y prescriptions of loop diuretics. The effect of clopidogrel
n these 2 HF groups showed equal results (data not
hown).
iscussion
his nationwide study evaluated the effect of clopidogrel on
ortality in patients admitted with first-time AMI who did
ot undergo PCI within 30 days. The principal finding was
14% relative risk reduction in mortality associated with
lopidogrel in patients with HF compared with patients
ithout clopidogrel. No mortality benefit with clopidogrel
mong patients without HF was observed. The importance
f this finding is underlined by the previously described low
nitiation rate of clopidogrel in AMI patients not receiving
CI and the fact that a substantial part of the patients not
eceiving clopidogrel had HF (12).
A favorable survival effect of clopidogrel in patients with
d 2 cohorts without HF. MI  myocardial infarction; PCI  percutaneous coro-
F  patients with or without HF; / PCI  patients treated with or withoutHF), an
/ HMI and HF may in part be explained by reduction of the
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Clopidogrel in HF in Connection With MI March 30, 2010:1300–7ncreased risk of atherothrombotic events (14). In the
ffects of CURE (Clopidogrel in Addition to Aspirin in
atients with Acute Coronary Syndromes without ST-
egment Elevation) study, clopidogrel prevented a compos-
te end point of cardiovascular death, AMI, or stroke in
atients with NSTEMI or unstable angina regardless of
oronary revascularization procedures. The effect of clopi-
ogrel was driven primarily by a reduction in recurrent AMI
7,21). The findings of the current study are compatible
ith the results of CURE, and the observed beneficial effect
f clopidogrel on the mortality of patients with AMI and
F may be related to a reduction of recurrent AMI. In
ontrast, no statistically significant benefit of clopidogrel on
ortality was shown in the CURE trial, although it should
e mentioned that CURE was not powered to demonstrate
reduction of mortality. We did not observe a similar
eduction of mortality in the cohort without HF. This could
e explained by a much lower possibility to detect a
ifference because these patients have a much better prog-
osis in general (7).
As mentioned in the previous text only a minor part of
aseline Characteristics of Propensity-Matched Population: Patienir t-Time Acute Mycarodial Infarction Without Perc t neous CoronTable 2 B seline Char cteristics of Propensity-Matched PopulaFirst-Time Acute Mycarodial Infarction Without Percuta
Heart Fail
Clopidogrel N
Total 11,142 2,525 (50.0) 2
Men 6,676 1,377 (54.5) 1
Age (yrs) 70.1 (12.6) 75.1 (10.0)
Year of admittance to hospital
Year 2000–2001 690 132 (5.2)
Year 2002–2003 5,172 1,075 (42.6) 1
Year 2004–2005 5,280 1,318 (52.2) 1
Comorbidity
Cerebral vascular disease 868 194 (7.7)
Diabetes with complications 783 290 (11.5)
Cardiac dysrhythmias 1,333 425 (16.8)
Acute renal failure 108 42 (1.7)
Chronic renal failure 210 86 (3.4)
Malignancy 350 104 (4.1)
Shock 102 41 (1.6)
Pulmonary edema 189 92 (3.6)
Severity of HF*
Group I 210 106 (4.2)
Group II 3,362 1,676 (66.4) 1
Group III 1,197 601 (23.8)
Group IV 281 142 (5.6)
Concomitant pharmacotherapy
Beta-blockers 8,888 1,912 (75.7) 1
ACE inhibitors 5,395 1,497 (59.3) 1
Statins 8,115 1,583 (62.7) 1
Glucose lowering drugs† 1,614 538 (21.3)
Vitamin K antagonist 674 223 (8.8)
Loop diuretic 5,050 2,525 (100) 2
alues are n (%) and/or mean  SD. *Loop diuretics are used as a proxy for heart failure. Accordi
9 mg; group II, 40 to 80 mg; group III, 81 to 160 mg; group IV, 160 mg). †Glucose-lowering dr
Abbreviations as in Table 1.atients in the CURE study had HF, and our study’s results cherefore add important knowledge regarding the use of
lopidogrel in post-AMI patients with HF. The random-
zed trial of COMMIT (Clopidogrel and Metoprolol in
yocardial Infarction Trial) evaluated the effect of adding
lopidogrel to aspirin in patients with AMI (8). In the
OMMIT study, severe HF was not an exclusion criterion
nd patients with HF therefore comprised a substantial part
f the study population (25% with Killip class II or III HF).
n this population, there was a 7% relative reduction in
ll-cause mortality up to 28 days after admission, which
eems to be in agreement with the benefits of clopidogrel in
atients with HF found in the present study (8).
HF is associated with increased risk of death after AMI,
nd therefore the recently documented low use of clopi-
ogrel in AMI patients treated without PCI is of concern
10–12). Part of the low use of clopidogrel is related first to
he study period (inclusion from 2000 through 2005) and
econd to exclusion of all patients undergoing primary PCI,
hich was nationally implemented in 2002. Lack of up-
ated knowledge of NSTEMI treatment guidelines among
hysicians may explain in part the low initiation rates of
mitted From 2000 through 2005 Withnterventi n and Survivin the First 30 DaysPa ients Admitted F m 2000 through 2005 With
s Coronary Intervention and Surviving the First 30 Days
 5,050) No Heart Failure (n  6,092)
idogrel p Value Clopidogrel No Clopidogrel p Value
(50.0) 1.00 3,046 (50.0) 3,046 (50.0) 1.00
(49.6) 0.48 1,958 (64.3) 1,989 (65.3) 0.41
(10.6) 0.46 65.7 (12.9) 66.1 (12.6) 0.28
(5.2) 1.00 213 (7.0) 213 (7.0) 1.00
(42.6) 1.00 1,511 (49.6) 1,511 (49.6) 1.00
(52.2) 1.00 1,322 (43.4) 1,322 (43.4) 1.00
(7.8) 0.92 148 (4.9) 148 (4.9) 1.00
(10.3) 0.16 118 (3.9) 116 (3.8) 0.89
(17.5) 0.53 227 (7.5) 239 (7.8) 0.56
(1.9) 0.59 9 (0.3) 10 (0.3) 0.82
(3.3) 0.81 21 (0.7) 20 (0.7) 0.88
(3.6) 0.31 82 (2.7) 74 (2.4) 0.52
(1.7) 0.83 10 (0.3) 8 (0.3) 0.64
(3.1) 0.32 9 (0.3) 9 (0.3) 1.00
(4.1) 0.89
(66.8) 0.77
(23.6) 0.87
(5.5) 0.85
(74.6) 0.36 2,548 (83.7) 2,544 (83.5) 0.89
(59.8) 0.73 1,184 (38.9) 1,205 (39.6) 0.58
(60.8) 0.16 2,508 (82.3) 2,490 (81.8) 0.55
(19.8) 0.17 304 (10.0) 273 (9.0) 0.18
(7.9) 0.34 119 (3.9) 132 (4.3) 0.40
(100) 1.00 0 (0.0) 0 (0.0)
erage daily dosage of loop diuretic (furosemide) in the first 90 days after discharge (group I, 0 to
d as a proxy of diabetes.ts Adary Ition:
neou
ure (n
o Clop
,525
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75.3
132
,075
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259
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March 30, 2010:1300–7 Clopidogrel in HF in Connection With MIigh cost could contribute, because clopidogrel is only partly
eimbursed. However, this seems to be a minor problem
n Denmark, because reimbursement is equal to all
atients independent of social status, participation in the
abor market, or availability of private health insurance
rograms (12).
Figure 2 Kaplan-Meier Survival Curve for Propensity-Matched P
Survival of matched populations with and without clopidogrel. HF  heart failure; M
Figure 3 HRs for Death According to Clopidogrel (No Treatmen
Two populations of patients with acute myocardial infarction with and without hear
on propensity score for receiving clopidogrel conditional of baseline covariates. 95Previously, Sørensen et al. (12) studied the pattern of
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umber of AMI patients treated without PCI (72%) stated
n the current study (Fig. 1) seems high; however, the
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8.1%, 34.3%, and 45.2%, respectively. Concerning the
attern of clopidogrel use, an average of 19.6% initiated
lopidogrel during the study period, and again, an increase
n practice is shown from 2.8%, to 24.4%, to 39.3%.
owever, during all periods, patients with HF were less
ikely to receive clopidogrel compared with patients without
F (12). Absence of evidence-based recommendations
egarding optimal antiplatelet therapy in post-AMI patients
ith HF may have discouraged physicians from prescribing
he drug. Similar considerations may apply to concerns
bout increased bleeding risk of dual antiplatelet therapy in
MI patients with HF, because these patients usually are
lder, take more concomitant medications, and may have
ignificant fluctuations in liver function, food intake, and
rug absorption (22). Thus, a future trial evaluating the
ffect of clopidogrel in patients with HF may provide an
mportant cornerstone in securing optimal treatment for this
atient group. In addition to the low initiation rates of
lopidogrel in AMI patients not undergoing PCI, these
atients also display a poor short-term adherence to clopi-
ogrel therapy. We previously demonstrated that from 2004
hrough 2005, only 71.6% of patients initially administered
lopidogrel actually completed 90 days of treatment, with
umbers further declining to 53.9% of patients completing
months of treatment (12). In our present Kaplan-Meier
nalysis (Fig. 2), the survival benefit of clopidogrel was
vident within the first year of follow-up, which underlines
he importance of encouraging patients to persist with
lopidogrel.
To our knowledge, this study is the first to evaluate the
ffect of clopidogrel on all-cause mortality in patients with
F and AMI who do not undergo PCI. Whether these
esults can be extrapolated to other patients with HF is
nknown. Two major randomized studies have been
aunched to examine the optimal antithrombotic therapy in
atients with HF, but the WATCH (Warfarin and Anti-
latelet Therapy in Heart Failure) trial was terminated
rematurely because of poor enrollment, and an interim
nalysis showed no difference between warfarin, aspirin, and
lopidogrel for a combined end point of all-cause mortality,
onfatal AMI, and nonfatal stroke (23), whereas results
rom the WARCEF (Warfarin versus Aspirin in Patients
ith Reduced Cardiac Ejection Fraction) study are pending
24). However, results from the literature support a benefi-
ial effect of clopidogrel in patients with HF. For example,
erebruany et al. (15) showed a significant inhibition of the
ncreased platelet activity in patients with HF after adding
lopidogrel to aspirin. Furthermore, Meune et al. (25)
bserved that in patients with HF receiving angiotensin
onverting enzyme inhibitors, aspirin had an adverse effect
n plasma concentrations of brain natriuretic peptides that
as not found with clopidogrel.
tudy strengths and limitations. The main strength of the
urrent study is the completeness of the data sample
overing the entire population of Denmark. We hereby mvoid selection bias related to, for example, age, sex,
illingness to participate in the study, demographic factors,
nd socioeconomic differences. The Danish National Pa-
ient Register diagnosis codes of AMI have been validated
reviously with a sensitivity of 91% and a positive predictive
alue of 93% (26). However, we were not able to distinguish
recisely between patients with ST-segment elevation myo-
ardial infarction and NSTEMI, because the register has
ot been validated with respect to these diagnosis codes.
he diagnosis code of HF has a sensitivity of 29% and a
ositive predictive value of 91% (27). To avoid underreport-
ng of cases with HF, we decided to include patients
eceiving treatment with loop diuretics in addition to those
ith an HF diagnosis (18). We performed subgroup mor-
ality analyses of these 2 HF groups independently and
ound equal results (data not shown). Potential underreport-
ng of HF, however, is likely to dilute any observed effect of
lopidogrel, and without under-reporting, the effect may
ave been even stronger. Likewise, 12.3% of the patients in
he matched population claimed a prescription beyond 30
ays from discharge and therefore constituted part of the
roup treated without clopidogrel. This may also weaken
he found effect of clopidogrel and therefore may strengthen
he validity of our results. Patients with diabetes were
dentified by use of glucose-lowering therapy, that is,
iabetes patients not requiring pharmacological treatment
ere not included in this group.
The Danish National Patient Register does not include
linical variables, for example, blood pressure, left ventric-
lar ejection fraction, brain natriuretic peptide levels, and
ther risk factors that could influence the patients’ progno-
is. Nor do we know whether the patients started clopi-
ogrel during the admission but stopped again because of
ide effects or drug intolerance. Also, we do not have
nformation about potential risks of bleeding or knowledge
f other risk or benefit considerations related to clopidogrel.
owever, the results include all-cause mortality, and fatal
leedings thus are included in the results. There is a risk of
onfounding by indication, for example, sicker patients are
ot prescribed clopidogrel and die shortly thereafter, regard-
ess of the drug. To ensure a more homogenous population,
e therefore included only patients who survived at least 30
ays after hospital discharge. Channeling bias also may be of
oncern, that is, healthier patients are more prone to receive
reatment than sicker patients. To diminish this potential
ias, we matched our populations according to propensity
core with a good discriminative power (C statistics 0.77),
ut we cannot rule out unknown risk factors or confounders
n the propensity match, and the current study cannot take
he place of a randomized trial (28). Finally, the use of
laimed prescriptions as a proxy of medical treatment in the
tudy population may imply bias, that is, the claimed
rescriptions may not correspond to the consumed medica-
ion. In Denmark, however, the medications of interest are
ispensed only with a valid prescription and all pharmacies
ust report every claimed prescription because of a national
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f dispensed drugs and diminishes the patient’s incentive to
btain medication through other sources. Moreover, the
anish Prescription Register has been shown to be highly
ccurate, and concordance between drug dispensing and
onsumption is likely to be high (16).
onclusions
he current study demonstrated an association between
lopidogrel and decreased mortality in patients with AMI
nd HF who do not undergo PCI. These patients have low
nitiation rates of clopidogrel and the data suggest that
ncreased awareness of the benefit of clopidogrel in such
igh-risk patients can have considerable clinical impact. A
andomized study of the effect of clopidogrel in patients
ith HF therefore is crucial to improve treatment of this
rowing patient population.
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